HSIC vs RYTM
Henry Schein vs Rhythm Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
RYTM
Rhythm Pharmaceuticals, Inc.
62
Buy
| Metric | HSIC | RYTM |
|---|
| AI Score |
67
|
62
|
| Price |
$89.16
|
$112.61
|
| P/E Ratio |
25.77×
|
-36.28×
|
| ROE |
12.3%
|
-72.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.3%
|
89.0%
|
| Debt / Equity |
1.21×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.4
|
59.9
|
| Beta |
0.808
|
1.974
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for HSIC versus RYTM.
HSIC leads by 5 points.
HSIC scores 67/100 (Buy) versus RYTM at 62/100 (Buy).
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
RYTM Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 53.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 16.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 53.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 26.5x prices in significant intangible value — Value
- ROE of only -80.5% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 16.3% signals elevated volatility — Risk